EGFR
16 drugsEpidermal Growth Factor Receptor
Predictive biomarker for patient selection in 19 indications
Understanding EGFR
What it means: EGFR is a receptor tyrosine kinase that, when mutated, drives uncontrolled cell growth. Common mutations include exon 19 deletions and L858R.
Why it matters: EGFR-mutant cancers respond dramatically to tyrosine kinase inhibitors (osimertinib, erlotinib, gefitinib).
Testing: Tested via next-generation sequencing (NGS) or PCR-based assays on tumor tissue or liquid biopsy (ctDNA).
16
Approved Drugs
19
Indications
14
Companies
EGFR is a precision-medicine biomarker linked to 16 FDA-approved targeted drugs from 14 companies, spanning 19 indications including Squamous Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer. Explore the targeted therapies, indications, testing methods, and companies developing EGFR drugs below.
Search EGFR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting EGFR
| Drug | Company | Therapeutic Area |
|---|---|---|
| ALUNBRIG | Takeda | Oncology |
| CAPRELSA | Sanofi | Oncology |
| ERBITUX | IMCLONE | Oncology |
| ERLOTINIB HYDROCHLORIDE | NATCO PHARMA LTD | Oncology |
| GEFITINIB | QILU PHARM HAINAN | Oncology |
| GILOTRIF | Boehringer Ingelheim | Oncology |
| HYRNUO | Bayer | Oncology |
| LAZCLUZE | Johnson & Johnson | Oncology |
| NERLYNX | PUMA BIOTECH | Oncology |
| PORTRAZZA | Eli Lilly | Oncology |
| RYBREVANT | Johnson & Johnson | Oncology |
| RYBREVANT FASPRO | Johnson & Johnson | Oncology |
| TAGRISSO | AstraZeneca | Oncology |
| TYKERB | Novartis | Oncology |
| VECTIBIX | Amgen | Oncology |
| VIZIMPRO | Pfizer | Oncology |
EGFR Indications
Squamous Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer Pancreatic Cancer Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapy First-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC First-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapy Metastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy Head and Neck Cancer Squamous Cell Carcinoma of the Head and Neck Colorectal Cancer BRAF V600E Mutation-Positive Metastatic Colorectal Cancer Breast Cancer Medullary Thyroid Cancer Metastatic Colorectal Cancer First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed) First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed) Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy (as a single agent)